Synergistic effect of combined protopanaxatiol and ginsenoside rh2 on antiproliferative activity in MDA-MB-231 human breast cancer cells in vitro

7Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Breast cancer is the most common cancer in women worldwide. The antiproliferative activities of protopanaxatiol (PPT) and ginsenoside Rh2 was measured by evaluating the inhibition of MDA-MB-231 human breast cancer cell proliferation. The two-way combination of PPT and Rh2 was conducted. In the two-way combination, the EC50 values of PPT and Rh2 were 2.3- and 2.2-fold lower, respectively, than those of PPT and Rh2 alone. The combination index (CI) values were 0.55 ± 0.09, 0.65 ± 0.10, 0.79 ± 0.12, and 0.91 ± 0.14 at 50% and 95% inhibition rates. Combined PPT and Rh2 also increased the inhibition of cell invasion and migration compared with individual compounds tested in cell lines. Intracellular signalling array analysis demonstrated that phosphorylated BAD, p53, and p38 proteins were increased. The results indicate that combined PPT and Rh2 exhibits a synergistic effect in MDA-MB-231 cell proliferation.

Cite

CITATION STYLE

APA

Ren, G., Wu, C., Teng, C., & Yao, Y. (2018). Synergistic effect of combined protopanaxatiol and ginsenoside rh2 on antiproliferative activity in MDA-MB-231 human breast cancer cells in vitro. Food and Agricultural Immunology, 29(1), 953–963. https://doi.org/10.1080/09540105.2018.1490700

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free